Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma
BackgroundImmune checkpoint inhibitors (ICIs) have been transformative in the treatment of patients with metastatic melanoma, but primary and secondary resistance to ICI treatment is common. One key mechanism for ICI resistance is the skewing of the im…